243 related articles for article (PubMed ID: 20117688)
1. Nursing care of clients treated with atypical antipsychotics who have a risk of developing metabolic instability and/or type 2 diabetes.
Edward KL; Rasmussen B; Munro I
Arch Psychiatr Nurs; 2010 Feb; 24(1):46-53. PubMed ID: 20117688
[TBL] [Abstract][Full Text] [Related]
2. Description of a healthy lifestyle intervention for people with serious mental illness taking second-generation antipsychotics.
Park T; Usher K; Foster K
Int J Ment Health Nurs; 2011 Dec; 20(6):428-37. PubMed ID: 21564457
[TBL] [Abstract][Full Text] [Related]
3. Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
Stahl SM; Mignon L; Meyer JM
Acta Psychiatr Scand; 2009 Mar; 119(3):171-9. PubMed ID: 19178394
[TBL] [Abstract][Full Text] [Related]
4. Putting metabolic side effects into perspective: risks versus benefits of atypical antipsychotics.
Meltzer HY
J Clin Psychiatry; 2001; 62 Suppl 27():35-9; discussion 40-1. PubMed ID: 11806488
[TBL] [Abstract][Full Text] [Related]
5. Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics.
Citrome LL; Holt RI; Zachry WM; Clewell JD; Orth PA; Karagianis JL; Hoffmann VP
Ann Pharmacother; 2007 Oct; 41(10):1593-603. PubMed ID: 17785613
[TBL] [Abstract][Full Text] [Related]
6. Assessment of a point-of-care metabolic risk screening program in outpatients receiving antipsychotic agents.
Schneiderhan ME; Batscha CL; Rosen C
Pharmacotherapy; 2009 Aug; 29(8):975-87. PubMed ID: 19637951
[TBL] [Abstract][Full Text] [Related]
7. Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes.
Silvestre JS; Prous J
Methods Find Exp Clin Pharmacol; 2005 Jun; 27(5):289-304. PubMed ID: 16082416
[TBL] [Abstract][Full Text] [Related]
8. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence.
Newcomer JW
J Clin Psychiatry; 2007; 68 Suppl 1():20-7. PubMed ID: 17286524
[TBL] [Abstract][Full Text] [Related]
9. Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring.
De Hert M; van Eyck D; De Nayer A
Int Clin Psychopharmacol; 2006 Mar; 21 Suppl 2():S11-5. PubMed ID: 16601508
[TBL] [Abstract][Full Text] [Related]
10. The comorbidity of diabetes mellitus and psychiatric disorders.
Medved V; Jovanović N; Knapić VP
Psychiatr Danub; 2009 Dec; 21(4):585-8. PubMed ID: 19935498
[TBL] [Abstract][Full Text] [Related]
11. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents.
McIntyre RS; Jerrell JM
Arch Pediatr Adolesc Med; 2008 Oct; 162(10):929-35. PubMed ID: 18838645
[TBL] [Abstract][Full Text] [Related]
12. Biological perspectives. Metabolic syndrome: schizophrenia and atypical antipsychotics.
Keltner NL
Perspect Psychiatr Care; 2006 Aug; 42(3):204-7. PubMed ID: 16916424
[No Abstract] [Full Text] [Related]
13. Metabolic complications of schizophrenia and antipsychotic medications--an updated review.
Yogaratnam J; Biswas N; Vadivel R; Jacob R
East Asian Arch Psychiatry; 2013 Mar; 23(1):21-8. PubMed ID: 23535629
[TBL] [Abstract][Full Text] [Related]
14. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs.
Newcomer JW
J Clin Psychiatry; 2004; 65 Suppl 18():36-46. PubMed ID: 15600383
[TBL] [Abstract][Full Text] [Related]
15. Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications.
Hasnain M; Vieweg WV; Fredrickson SK; Beatty-Brooks M; Fernandez A; Pandurangi AK
Prim Care Diabetes; 2009 Feb; 3(1):5-15. PubMed ID: 19083283
[TBL] [Abstract][Full Text] [Related]
16. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
17. Metabolic and endocrine disturbances in psychiatric disorders: a multidisciplinary approach to appropriate atypical antipsychotic utilization.
Masand PS; Culpepper L; Henderson D; Lee S; Littrell K; Newcomer JW; Rasgon N
CNS Spectr; 2005 Oct; 10(10):suppl14 1-15. PubMed ID: 16404802
[TBL] [Abstract][Full Text] [Related]
18. The implications of weight changes with antipsychotic treatment.
Sussman N
J Clin Psychopharmacol; 2003 Jun; 23(3 Suppl 1):S21-6. PubMed ID: 12832946
[TBL] [Abstract][Full Text] [Related]
19. Metabolic syndrome and associated cardiovascular risk factors in the treatment of persons with human immunodeficiency virus and severe mental illness.
Vergara-Rodriguez P; Vibhakar S; Watts J
Pharmacol Ther; 2009 Dec; 124(3):269-78. PubMed ID: 19647020
[TBL] [Abstract][Full Text] [Related]
20. Metabolic syndrome and mental illness.
Newcomer JW
Am J Manag Care; 2007 Nov; 13(7 Suppl):S170-7. PubMed ID: 18041878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
